Drug Trial Radar · NCT04834869
COVID-19 Vaccines Safety Tracking (CoVaST)
Last checked: Nov 20, 2026Latest source record: Apr 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30,000
Planned (sponsor's estimate)
Start
Apr 1, 2021
Primary completion
Dec 31, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Masaryk UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 8, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This project aims to monitor the side effects of COVID-19 vaccines worldwide actively. The primary objectives of the project include a) to estimate the prevalence of each local and systemic side effect of each COVID-19 vaccine among healthcare workers (HCW), old adults over +65 (OA), and schoolteachers (ST); b) to evaluate the potential demographic and medical risk factors for side effects frequency and intensity; c) to evaluate the long-term consequences of COVID-19 vaccines. The secondary objectives include a) to evaluate the relative safety of COVID-19 vaccines compared to each other; b) to evaluate the impact of palliative drugs used by the recently vaccinated individuals on their short-term side effects resolution.
Conditions
- Adverse Reaction to Vaccine
- COVID19 Vaccine
Interventions
BNT162b2Biological
Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)
mRNA-1273Biological
Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)
AZD1222Biological
Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)
CoronaVacBiological
Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)
SinopharmBiological
Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine
Gam-COVID-VacBiological
Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)
JNJ-78436735Biological
Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)
CVnCoVBiological
Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)
NVX-CoV2373Biological
Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)
BBV152Biological
Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Local Side EffectsTime frame: 0-30 days after the COVID-19 vaccine shot
- Systemic Side EffectsTime frame: 0-30 days after the COVID-19 vaccine shot
Locations
14 sites in 14 countries. Site status is shown where the registry gives one.
American College of Physicians
Philadelphia, Pennsylvania · Not yet recruiting
McMaster University
Hamilton, Ontario, Canada · Not yet recruiting
University of Split
Split, Croatia · Not yet recruiting
Masaryk University
Brno, Czechia · Recruiting
University of Tartu
Tartu, Estonia · Not yet recruiting
Jimma University
Jimma, Ethiopia · Recruiting
Justus-Liebig University Giessen
Giessen, Germany · Recruiting
University of Ghana
Accra, Ghana · Not yet recruiting
Sinaloa's Pediatric Hospital
Culiacán, Mexico · Not yet recruiting
Medical University of Silesia
Katowice, Poland · Recruiting
Nursing School of Coimbra
Coimbra, Portugal · Not yet recruiting
Irkutsk Scientific Center of Siberian Branch of Russian Academy of Sciences
Irkutsk, Russia · Recruiting
University of Belgrade
Belgrade, Serbia · Recruiting
University of Ljubljana
Ljubljana, Slovenia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.